JP2015117185A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015117185A5 JP2015117185A5 JP2013259713A JP2013259713A JP2015117185A5 JP 2015117185 A5 JP2015117185 A5 JP 2015117185A5 JP 2013259713 A JP2013259713 A JP 2013259713A JP 2013259713 A JP2013259713 A JP 2013259713A JP 2015117185 A5 JP2015117185 A5 JP 2015117185A5
- Authority
- JP
- Japan
- Prior art keywords
- deuterium
- hydrogen
- compound
- compound according
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 17
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 13
- 229910052805 deuterium Inorganic materials 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 239000001257 hydrogen Substances 0.000 claims 13
- 206010028537 myelofibrosis Diseases 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 3
- 230000000155 isotopic effect Effects 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 208000032027 Essential Thrombocythemia Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 229960004117 capecitabine Drugs 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 229960000255 exemestane Drugs 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- FWZRWHZDXBDTFK-ZHACJKMWSA-N panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 claims 2
- 229960005184 panobinostat Drugs 0.000 claims 2
- 208000003476 primary myelofibrosis Diseases 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 208000017733 acquired polycythemia vera Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000037244 polycythemia vera Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013259713A JP6367545B2 (ja) | 2013-12-17 | 2013-12-17 | ルキソリチニブの重水素化誘導体 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013259713A JP6367545B2 (ja) | 2013-12-17 | 2013-12-17 | ルキソリチニブの重水素化誘導体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018128417A Division JP6830460B2 (ja) | 2018-07-05 | 2018-07-05 | ルキソリチニブの重水素化誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015117185A JP2015117185A (ja) | 2015-06-25 |
| JP2015117185A5 true JP2015117185A5 (enExample) | 2017-02-09 |
| JP6367545B2 JP6367545B2 (ja) | 2018-08-01 |
Family
ID=53530252
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013259713A Active JP6367545B2 (ja) | 2013-12-17 | 2013-12-17 | ルキソリチニブの重水素化誘導体 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP6367545B2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7068827B2 (ja) | 2015-06-30 | 2022-05-17 | アイガー グループ インターナショナル インコーポレイテッド | 炎症性状態および癌性状態を治療するための、クロロキン化合物およびクレミゾール化合物の使用 |
| KR102053556B1 (ko) * | 2015-09-29 | 2020-01-08 | 강푸 바이오파마슈티칼즈 리미티드 | 약물 조성물 및 이의 응용 |
| ES2988629T3 (es) * | 2016-05-04 | 2024-11-21 | Sun Pharmaceutical Ind Inc | Tratamiento de trastornos de pérdida de cabello con inhibidores de JAK deuterados |
| CN108368134B (zh) | 2016-07-25 | 2019-06-14 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的硼酸化合物及包含该化合物的药物组合物及其用途 |
| JP6830460B2 (ja) * | 2018-07-05 | 2021-02-17 | コンサート ファーマシューティカルズ インコーポレイテッド | ルキソリチニブの重水素化誘導体 |
| GB201907871D0 (en) * | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| AU2021206286A1 (en) * | 2020-01-10 | 2024-08-08 | Consynance Therapeutics, Inc. | Therapeutic combinations of drugs and methods of using them |
| EP3902541B1 (en) * | 2020-06-02 | 2022-09-14 | Small Pharma Ltd | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS55634B1 (sr) * | 2005-12-13 | 2017-06-30 | Incyte Holdings Corp | Heteroaril substituisani pirolo[2,3-b]piridini i pirolo[2,3-b]pirimidini kao inhibitori janus kinaze |
| TWI531572B (zh) * | 2010-03-10 | 2016-05-01 | 英塞特公司 | 作為ｊａｋ１抑制劑之哌啶－４－基三亞甲亞胺衍生物 |
-
2013
- 2013-12-17 JP JP2013259713A patent/JP6367545B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015117185A5 (enExample) | ||
| PH12014501542A1 (en) | Substituted pyrrolidine -2- carboxamides | |
| PH12018502125A1 (en) | Bipyrazole derivatives as jak inhibitors | |
| MX2015012432A (es) | Inhibidores piridinicos de la cinasa cdk9. | |
| JP2017008088A5 (enExample) | ||
| MX395482B (es) | Compuestos antiproliferativos y metodos de uso de los mismos | |
| TR201807411T4 (tr) | DNA-PK inhibitörleri. | |
| JP2015533176A5 (enExample) | ||
| GEP201606560B (en) | Macrocyclic derivatives for the treatment of proliferative diseases | |
| GB201205669D0 (en) | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof | |
| NZ715747A (en) | Syk inhibitors | |
| PH12014502341A1 (en) | Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments | |
| MX379425B (es) | 7-bencil-4-(2-metilbencilo) -2,4,6,7,8,9-hexahidroimidazo [1,2-a] pirido [3,4-e] pirimidin-5 (1h) -ona, análogos y sales del mismo y su uso en terapia. | |
| MX345928B (es) | Composiciones terapeuticamente activas y metodos de uso de las mismas. | |
| JP2016501221A5 (enExample) | ||
| BR112015001502A2 (pt) | derivados de tipo azaindazol ou diazaindazol para tratamento de dor | |
| NZ726366A (en) | Syk inhibitors | |
| JP2017514910A5 (enExample) | ||
| JP2015500885A5 (enExample) | ||
| JP2015502926A5 (enExample) | ||
| GEP201706741B (en) | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | |
| JP2015500884A5 (enExample) | ||
| PH12015501945B1 (en) | Formulations of organic compounds | |
| CY1120602T1 (el) | [1,2,4]τριαζολο[4,3-β]πυριδαζινες για χρηση στη θεραπευτικη αντιμετωπιση πολλαπλασιαστικων ασθενειων | |
| JP2013544892A5 (enExample) |